Public log · Updated May 19, 2026
Changelog
What we've changed, verified, and shipped on GLP-1 Picks. Every provider re-verification, every new article, every methodology update. Reverse-chronological, append-only, public on day one. The long version of our editorial policy.
May 2026 · 21 entries
- May 19Article shipped
Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound
Updated May 19, 2026: The BALANCE Model Part D pilot was canceled April 21, 2026 — the Medicare GLP-1 Bridge is now the ONLY federal Medicare obesity pathway through December 31, 2027. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, a…
- May 17Provider re-verified
bmiMD review — re-verified
bmiMD trades on scale — 80,000+ customers and same-day physician consults give it legitimacy that newer platforms lack. The $50 cancellation fee and $29.99 shipping are drawbacks most competitors have eliminated. The TAKEOFF $100-off 3-month entry brings first-month semaglutide t…
- May 17Provider re-verified
WeightWatchers (Sequence) review — re-verified
WeightWatchers' GLP-1 program makes sense for users who already love WW and want to add medication, or those with insurance who can bring the cost down. The community and structured approach add genuine value for the right user. But at $423/mo all-in ongoing self-pay (and $149-$2…
- May 13Provider re-verified
Eden Health GLP-1 review — re-verified
Eden Health is the most clinically thorough GLP-1 platform we've reviewed — board-certified obesity medicine doctors and quarterly labs are real differentiators, and 4.5 stars across 3,777 Trustpilot reviews backs the customer-experience claim. Pricier than budget options like He…
- May 13Provider re-verified
Henry Meds review — re-verified
Henry Meds has the strongest verified customer-experience signal in our table — 12,461 Trustpilot reviews at 4.5 stars, 85% 5-star. Best for people who want a well-tested platform with the flexibility to switch between compounded and brand-name medications. The main transparency…
- May 13Provider re-verified
Hims review — re-verified
Hims has the strongest brand recognition and one of the few direct Novo Nordisk partnerships for FDA-approved Wegovy. But the verified Trustpilot rating (3.0 across 8,286 reviews, 28% 1-star) is the weakest in our table — the lowest customer-experience signal among major affiliat…
- May 13Provider re-verified
Yucca Health review — re-verified
Yucca Health has the strongest customer-experience signal of any compounded GLP-1 provider we've checked — 4.6 stars across 1,065 Trustpilot reviews, two named board-certified doctors, and Klarna/Affirm/Afterpay financing on the 6-month plan. Best at $146/mo if you'll commit to t…
- May 13Article shipped
Compounded Semaglutide Ban (2026): FDA Crackdown Explained + 4 Legal Switch Options
Updated May 2026: FDA proposed on April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — effectively closing the door on large-scale compounding if finalized. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 mi…
- May 13Editorial / methodology
Publish-cadence cap announced
While at DR 0 with lifetime affiliate revenue below $500, new articles are capped at 2 per week. Every new article requires verified primary-source data — articles whose sources can't be independently checked are deferred, not shipped. The freed publishing capacity routes to revi…
- May 12Provider re-verified
Embody review — re-verified
Embody is fine if you pick the right plan — but the $149 teaser isn't your long-term price, and most negative reviews come from people who didn't realize that. The oral tirzepatide gum is a real differentiator. For predictable long-term pricing, switch to 'Embody Flat' at signup…
- May 12Article shipped
IvyRx GLP-1 Review 2026: Flat-Rate Compounded Semaglutide & Tirzepatide at $175–$297/mo
IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model — your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valu…
- May 12Editorial / methodology
Embody review v2 — full verification pass
Re-verified Embody end-to-end via live-site crawl: pricing, medical director, compounding pharmacy partners, customer evidence, aggregate review scores. Six logical chapters with sticky TOC, plain-English methodology, no jargon. The template replicated weekly on the next click-wi…
- May 11Article shipped
Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss — $149 vs $1,349/mo Self-Pay
Updated May 18, 2026 with Week 5 IQVIA data: 10,248 weekly Rx (+40% week-over-week re-acceleration). Oral Wegovy produces 16.6% body weight loss vs Foundayo's 12.4%, but Foundayo starts at $149/mo self-pay (WAC $649/mo) vs Wegovy's $1,349/mo and has no fasting requirement. PBM fo…
- May 9Editorial / methodology
Provider Anchor audit script + GATE 3
Every reference to a provider's price across the codebase now traces to providers.ts. The audit script flags any drift between the canonical price and stale references in blog posts or components. Wired into the pre-push gate so price changes can't ship without consistency.
- May 8Article shipped
FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide
Verified May 8, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list — forever, not just during shortage enforcement. Public comment closes June 29, 2026. If finalized, no 503B pharmacy could bulk-compo…
- May 7Article shipped
Tirzepatide Dosage Chart for Weight Loss 2026: Complete Schedule (Zepbound, Mounjaro & Compounded)
Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1 — equivalent…
- May 5Article shipped
Next Weight Loss Drugs Pipeline (2026): Retatrutide 28.7%, CagriSema 22.7%, MariTide Monthly
Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 202…
- May 4Editorial / methodology
Scoring rubric 2026 — published
Five-axis weighted methodology (Cost 25%, Clinical 25%, Medication options 20%, UX 15%, Insurance 15%) with public scoring-evidence.json. Every score traces to evidence flags; the build fails if a verified provider drifts from its computed score.
- May 1Provider re-verified
Gala review — re-verified
Gala is a tirzepatide-first compounded GLP-1 platform with two genuine strengths: (1) the cheapest microdose tirz tier on any tracked platform at $149/mo, and (2) a dedicated tracker app on BOTH iOS and Android (most compounded-only platforms have neither). Third-party accountabi…
- May 1Provider re-verified
SkinnyRx review — re-verified
SkinnyRx wins on medication-format breadth — five compounded GLP-1 options across injectable, sublingual, and tablet formats, including the unusually rare oral tirzepatide tablet. The $199/mo entry tier matches the mid-tier compounded average, the 24–48h physician review and 3–7…
- May 1Provider re-verified
Bodybuilding Health+ review — re-verified
Bodybuilding Health+ is the brand-license play — a Dynamo Group LLC platform marketed under the Bodybuilding.com banner, with a narrow but competitively-priced compounded-GLP-1 menu ($179 sema, $209 tirz) and a multi-program account that also covers peptides (NAD+, Sermorelin) an…
April 2026 · 68 entries
- April 29Article shipped
Foundayo (Orforglipron) Guide 2026: $649/mo, 12.4% Weight Loss, No Fasting Required
Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700…
- April 23Editorial / methodology
First affiliate conversion
Eden Health, $300 payout. Validated the funnel: organic search → review page → affiliate click → conversion. The unit economics check out; the bottleneck is volume, not the funnel.
- April 22Article shipped
Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels — Which Is Right for You?
Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List pr…
- April 20Article shipped
Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13% — Full Guide with SURMOUNT Trial Data
Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials — nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within…
- April 17Article shipped
GLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25–$1,350/mo)
How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $115/mo compounded sema (Enhance MD), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect…
- April 16Article shipped
RFK Jr. Proposes Medicare GLP-1 'Framework' (April 2026): Glucose Monitors First, Coverage Second
HHS Secretary Robert F. Kennedy Jr. is considering a regulatory framework for Medicare and Medicaid GLP-1 coverage, but only for patients who have 'exhausted other options' — specifically glucose monitors (~$80/month), diet changes, and exercise. Verified April 2026: what Kennedy…
- April 14Article shipped
Medicare GLP-1 Coverage: Everything Changing in July 2026
Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.
- April 13Article shipped
GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide
FDA-approved GLP-1 receptor agonists for weight loss — 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified…
- April 11Article shipped
Brand vs Compounded GLP-1 (2026): $349 Wegovy vs $149 Compound — Legal Status + Safety
Verified April 2026: Brand-name Wegovy is $349/mo via NovoCare, Zepbound starts at $299/mo via LillyDirect. Compounded semaglutide is banned since Feb 2025; compounded tirzepatide remains legal at $149-299/mo under narrow medical-necessity rules. Full legal + safety comparison.
- April 11Article shipped
First Month on GLP-1 (2026): 2-5 lbs Lost Week 1-4, Nausea Peaks Week 4 — Week-by-Week
Verified April 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing sched…
- April 11Article shipped
Retatrutide (2026): 28.7% Weight Loss, Phase 3 Triple-Agonist — FDA Approval Late 2027
Verified April 2026: Retatrutide (Eli Lilly, LY-3437943) achieved 28.7% body weight loss in Phase 3 TRIUMPH trials — nearly double semaglutide (14.9%) and 37% higher than tirzepatide (20.9%). First triple-agonist (GLP-1 + GIP + glucagon). FDA approval expected late 2027 to early…
- April 11Article shipped
Wegovy vs Zepbound (2026): 14.9% vs 20.9% Weight Loss, $349 vs $449/mo
Verified April 2026: Zepbound (tirzepatide) produces 20.9% body weight loss vs Wegovy's (semaglutide) 14.9% per the SURMOUNT-1 and STEP-1 trials. Wegovy self-pay: $349/mo (NovoCare). Zepbound self-pay: $299-$449/mo (LillyDirect). Both $25/mo with commercial insurance + savings ca…
- April 11Article shipped
Medicare GLP-1 Coverage July 2026: $50/mo Wegovy + Zepbound Bridge Program Guide
Verified April 2026: Medicare Part D begins covering Wegovy and Zepbound for weight loss July 1, 2026 via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Runs through Dec 31, 2026, then permanent BALANCE Model launches January 2027.
- April 11Article shipped
Ozempic vs Wegovy (2026): Same Drug, $1,028 vs $1,349 List — Here's Which You Need
Verified April 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,028/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). Both drop to $349/mo self-pay via NovoCare.
- April 11Article shipped
Wegovy Pill vs Injection (2026): 16.6% vs 14.9% Weight Loss, $1,349 vs $349/mo
Verified April 2026: Oral Wegovy (25mg daily pill) produces 16.6% weight loss per the OASIS trial vs 14.9% for injectable Wegovy (2.4mg weekly) per STEP-1. Pill costs $1,349/mo list vs $349/mo self-pay for the injection through NovoCare. Full head-to-head comparison.
- April 11Article shipped
Semaglutide vs Tirzepatide (2026): 13.7% vs 20.2% Weight Loss — Head-to-Head SURMOUNT-5
Verified April 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial (NEJM). Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Tirzepatide costs $449/mo vs $349/mo self-pay. Full comparison.
- April 11Article shipped
Foods to Avoid on GLP-1 (2026): 7 Worst Offenders + What to Eat Instead
Verified April 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound — fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alter…
- April 11Article shipped
GLP-1 Side Effects (2026): Nausea 44%, Diarrhea 30%, Vomiting 24% — Complete Management Guide
Verified April 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.
- April 11Article shipped
Tirzepatide Cost 2026: $149 to $1,086/Month — Every Option Ranked (Verified April 2026)
Verified April 2026: Tirzepatide costs $149/mo via Enhance MD (compounded), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $449/mo for LillyDirect 5mg+ vials, $25/mo with Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 47 verified providers.
- April 11Article shipped
Compounded Tirzepatide (2026): $149/mo Legal Options, Safety, Medical-Necessity Rules
Verified April 2026: Tirzepatide compounding enforcement began March 2025 after FDA removed it from the shortage list. Narrow medical-necessity exemptions still allow legal compounded tirzepatide at $149-300/mo (vs $1,086/mo retail Zepbound). Complete legal framework, safety, and…
- April 11Article shipped
Zepbound & Mounjaro Savings Card (2026): $25/mo Copay + $1,300 Annual Savings
Verified April 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup option…
- April 11Article shipped
Foundayo Ships Week 2: How to Order Eli Lilly's GLP-1 Pill Right Now (April 2026)
Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.
- April 11Article shipped
FDA Issues 14 New GLP-1 Compounder Warning Letters (March-April 2026 Enforcement)
Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026 — the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.
- April 11Article shipped
Medicare GLP-1 Bridge: 81 Days Until $50/Month Wegovy and Zepbound (April 2026 Countdown)
Verified April 11, 2026: 81 days until the Medicare GLP-1 Bridge launches July 1, 2026. Complete prep checklist: Part D enrollment verification, BMI documentation, comorbidity coding, prior auth prep. Free Medicare Eligibility Checker tool inside.
- April 10Editorial / methodology
Canonical tags on every page
Next.js App Router does not emit canonicals automatically from metadataBase — every route now explicitly exports alternates.canonical via metadata or generateMetadata. GATE 4 enforces this pre-push for any new template.
- April 10Editorial / methodology
Provider count 40 → 46 → 48
Expanded coverage to include Yucca Health, Gala, Embody, Bodybuilding Health+, and others. Every comparison page is template-generated, so n × (n-1) / 2 matchups stay in sync automatically.
- April 8Article shipped
Semaglutide Before and After: Weight Loss Results by Month
Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.
- April 8Article shipped
GLP-1 Patches for Weight Loss: Do They Actually Work? (2026 Fact Check)
GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.
- April 3Article shipped
Ro vs Hims for GLP-1 Weight Loss: Which Is Better in 2026?
Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.
- April 2Article shipped
Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime
The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
- April 1Provider re-verified
Willow review — re-verified
Willow is a solid mid-tier compounded-only GLP-1 platform. At $299/mo compounded semaglutide (injectable or daily oral) and $399/mo compounded tirzepatide, pricing is above ultra-cheap options like Sesame Care but reflects real clinical oversight. The oral semaglutide daily table…
- April 1Provider re-verified
Sprout Health review — re-verified
Sprout Health is the premium reliable choice — you pay more, but you get a level of consistency and dedicated support that newer platforms haven't yet proven. The published outcomes data and dedicated coordinator model justify the price for users who want peace of mind. For budge…
- April 1Provider re-verified
Fridays review — re-verified
Fridays is the best choice for users with GLP-1 insurance coverage — the direct billing can bring costs down to $25-50/mo, which is unbeatable. The nutrition coaching adds genuine value for users who want more than just medication. Without insurance, the $249/mo price is harder t…
- April 1Provider re-verified
Ro review — re-verified
Ro is the safest bet for insured users who want brand-name GLP-1 medications from a trusted platform. The speed, insurance integration, and brand recognition are unmatched. The trade-off is no compounded options and high self-pay prices — if you don't have insurance coverage, pla…
- April 1Provider re-verified
TrimRx review — re-verified
TrimRx is the best value for users who specifically want compounded semaglutide without extras. The $179/mo all-inclusive price, fast onboarding, and replacement guarantee make it a standout in the budget compounded space. Just know that you're locked into one medication type wit…
- April 1Provider re-verified
Enhance MD review — re-verified
Enhance MD is the smart budget choice for self-directed users who know what they want. The $115/mo entry price for both medication types is hard to beat, and the combination therapy options are a unique bonus. Just be prepared to manage your own care — this is not a hand-holding…
- April 1Provider re-verified
MEDVi review — re-verified
MEDVi is the best option for needle-averse users who want a clear pathway from oral to injectable GLP-1 treatment. The micro-dosing options, sleek portal, and 2026 expansion to compounded tirzepatide (both injectable and oral tablet) plus brand-name Ozempic broaden the platform's…
- April 1Provider re-verified
Sesame Care review — re-verified
Sesame Care is the most cost-effective path to a GLP-1 prescription for insured patients. At $25 per consultation with no subscription lock-in, it's ideal for users who just need a prescriber and will handle medication through their insurance. For uninsured users or those wanting…
- April 1Provider re-verified
Strut Health review — re-verified
Strut Health does one thing well: needle-free GLP-1 at a fair price. The $199/mo flat rate is straightforward, and the oral format eliminates injection anxiety. The limitation is real — oral compounded semaglutide has lower bioavailability than injectable, and with FDA-approved o…
- April 1Provider re-verified
Ivim Health review — re-verified
Ivim restructured into package pricing — sema at $900 for 12 months (plus $75 mandatory membership) works out to $150/mo all-in, which is competitive. Tirz at $1,600 for 12 months is $208/mo all-in. Klarna financing available. Best for users who can commit to 6-12 months upfront.
- April 1Provider re-verified
Hone Health review — re-verified
Hone Health is the most medically thorough option on this list — the 40+ biomarker panel is genuinely more comprehensive than any competitor's intake process. But the layered pricing ($65 + $149/mo + medication) makes it 2-3x the cost of focused weight-loss platforms. Best for pa…
- April 1Provider re-verified
Found review — re-verified
Found is the clear winner for insured patients. The insurance coordination service and GLP-1 coverage check are features most competitors simply don't offer. The 10+ medication toolkit gives clinicians flexibility that single-medication platforms can't match. Cash-pay at $129/mo…
- April 1Provider re-verified
MyStart Health review — re-verified
MyStart Health offers solid value with its Price Lock Guarantee and competitive $149-179/mo pricing. The unlimited clinician access and 600+ doctor network are genuine strengths. The limitations — cash-pay only, select states, no brand-name options — keep it from competing with p…
- April 1Provider re-verified
AgelessRx review — re-verified
AgelessRx is genuinely different — the longevity medicine framework, microdosing protocols, and no-membership model set it apart from cookie-cutter GLP-1 platforms. The liraglutide + B12 at $149/mo (+ $50 oversight) is the value play. Semaglutide at $340/mo total is overpriced fo…
- April 1Provider re-verified
Direct Meds GLP-1 review — re-verified
Direct Meds charges $280/mo but positions itself as more clinically thorough. If clinical depth matters more than price, it delivers; if budget matters, competitors offer the same medication for $100-150 less.
- April 1Provider re-verified
Fella Health review — re-verified
Fella's brand-name-only approach is a bold bet on quality over price. The 6-month money-back guarantee is one of the strongest in the industry and shows real confidence. At $165/mo with a year commitment, it's actually competitive for brand-name GLP-1 access. The men-only focus m…
- April 1Provider re-verified
Maximus review — re-verified
Maximus is the cheapest way to try GLP-1 therapy — the $79.99 microdose and $99.99 starter are unmatched. The innovation around microdosing for lower-BMI patients fills a real gap. But the layered pricing (separate consultations, labs, and post-intro price increases) means real o…
- April 1Provider re-verified
TMates review — re-verified
TMates' 2026 expansion creates two distinct use cases: (1) cheap long-term compounded GLP-1 access via multi-month commitment ($158/mo on 12-mo plan), and (2) cheap clinical service for brand-name Wegovy/Zepbound at $99/mo where you source the medication yourself. The $99 brand t…
- April 1Provider re-verified
Mochi Health review — re-verified
Mochi Health is the best value play for patients planning to stay on GLP-1 long-term at therapeutic doses. The flat $99/mo pricing saves real money compared to platforms that scale with dose. Four semaglutide formats and registered dietitian access are unique differentiators. The…
- April 1Provider re-verified
Elevate Health review — re-verified
Elevate Health's oral semaglutide at $114/mo is a standout price point, and the BNPL financing removes a real barrier for patients who can't afford $200+/mo upfront. Free blood work adds clinical value. The risk is promo-dependent pricing — lock in rates before enrolling and unde…
- April 1Provider re-verified
DudeMeds review — re-verified
DudeMeds is the simplest GLP-1 platform to use — $199/mo all-in, 48-hour shipping, zero complexity. The trade-off is minimal clinical oversight. The lack of transparent company details (no public HQ, no founding date) is a concern, but the straightforward pricing and fast shippin…
- April 1Provider re-verified
Zealthy review — re-verified
Zealthy is built for insured patients. If their insurance coordinators successfully get your brand-name GLP-1 covered, you're looking at potentially $25/mo — unbeatable value. The multi-month supply option is a unique convenience. For cash-pay patients, the ~$286/mo total (medica…
- April 1Provider re-verified
SynergyRx review — re-verified
The oral dissolving tablet format for both semaglutide and tirzepatide sets SynergyRx apart from most competitors. Free expedited shipping and 24/7 support are strong additions. The concern is legitimacy — limited reviews, Wyoming registration, and no transparent company history.…
- April 1Provider re-verified
PeterMD review — re-verified
PeterMD delivers genuine value at $165/mo flat with a semaglutide + B12 formulation that addresses the nausea problem most patients fear. The 100,000+ patient base and strong Trustpilot reviews provide social proof. The limitations — 42 states only, no BBB accreditation, and some…
- April 1Provider re-verified
MangoRx review — re-verified
MangoRx fills a specific niche: oral-only GLP-1 with public-company accountability. The NASDAQ listing is a genuine trust signal. But at $299-399/mo for compounded oral tablets, it's expensive compared to $99-179/mo injectable alternatives. The company is early-stage with limited…
- April 1Provider re-verified
Care Bare Rx review — re-verified
CareBareRX's flat $199/mo for both oral and injectable options is straightforward, and the named physician leadership adds a trust layer. The friendly branding differentiates in a space of sterile clinical sites. But the lack of any verifiable company information — no founding da…
- April 1Provider re-verified
Breeze Meds review — re-verified
The no-subscription model is BreezeMeds' main selling point — useful for patients who want flexibility without billing commitments. The three formulation options add value. But the company's legitimacy is the biggest concern: confusingly similar entities exist, independent review…
- April 1Provider re-verified
Hers review — re-verified
The 2026 Novo Nordisk partnership makes Hers materially different from where it was a year ago — FDA-approved Wegovy pen and pill from $149/mo is one of the cheapest brand-name GLP-1 routes available. Compounded semaglutide stays at $199/mo, and compounded tirzepatide and Zepboun…
- April 1Provider re-verified
Noom Med review — re-verified
Noom Med is the best choice for users who believe lasting weight loss requires behavior change alongside medication. The coaching methodology is research-backed and the integration with GLP-1s is thoughtful. At $249/mo without insurance, it's expensive if you mainly want the medi…
- April 1Provider re-verified
GobyMeds review — re-verified
GobyMeds is the best budget pick for compounded semaglutide in 2026. The $119/mo price, fast delivery, and strong user reviews make it a standout value. The trade-off is limited medication options and a shorter track record. For users who specifically want affordable compounded s…
- April 1Provider re-verified
Lemonaid Health review — re-verified
Lemonaid Health offers the credibility and medical rigor that comes with being one of the oldest telehealth platforms in the GLP-1 space. The physician-only prescribing and thorough intake process exceed most competitors. However, the $229/mo price for compounded medication is ha…
- April 1Provider re-verified
Calibrate review — re-verified
Calibrate in 2026 is cleaner and cheaper than it was — the $1,649 enrollment fee is gone, replaced by $199/mo with a 3-month commitment. You still get the structured physician-led program (labs, coaching, smart scale) plus a 10%+ weight-loss guarantee. Best for users who want cli…
- April 1Provider re-verified
GoodRx Care review — re-verified
GoodRx Care is a convenient prescription pathway for users already in the GoodRx ecosystem, especially those with insurance. The discount integration is genuinely useful for finding the cheapest pharmacy prices. But as a GLP-1 program, it's bare-bones — no ongoing support, no med…
- April 1Provider re-verified
Shed review — re-verified
Shed is the fastest way to start GLP-1 treatment — 2-3 days from signup to medication delivery is genuinely market-leading. At $149/mo for compounded semaglutide with both semaglutide and tirzepatide options, the pricing is competitive. The main concern is the company's youth — f…
- April 1Provider re-verified
Oak Longevity review — re-verified
Oak Longevity competes on price and a unique no-subscription billing model. $130/mo compounded semaglutide and $199/mo tirzepatide are at the lower end of the market, the manual-renewal billing avoids the subscription regret trap, and the broad medication menu (including a $100 o…
- April 1Provider re-verified
Tonik Wellness review — re-verified
Tonik Wellness is a fair mid-tier compounded GLP-1 option with a clear strength (transparent six-tier monthly/quarterly/annual pricing on both semaglutide and tirzepatide) and a clear weakness (a 3-month minimum commitment plus final-sale rules that more flexible competitors like…
- April 1Provider re-verified
Novi review — re-verified
Novi is a credible upper-mid-tier compounded GLP-1 option with three clear strengths (six named clinicians, month-to-month billing with no commitment, aggressive $99-$133/mo introductory promo pricing) and the standard set of compounded-only weaknesses (no brand-name access, no o…
- April 1Provider re-verified
Wellorithm review — re-verified
Wellorithm earns its 7.4 score by offering two genuinely uncommon features — compounded GLP-1 in oral dissolving tablet format alongside the standard injectable, and a 10% weight-loss money-back guarantee with up to four months of fees refundable if the patient does not hit the o…